HER2, Active
Recombinant human HER2 (676-end) was expressed by baculovirus in Sf9 insect cells using a N-terminal GST tag.
Catalog No. E27-11G
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| E27-11G-05 | 5 ug | $226 | |
| E27-11G-10 | 10 ug | $325 | |
| E27-11G-BULK | BULK | Contact Us |
Recombinant human HER2 (676-end) was expressed by baculovirus in Sf9 insect cells using a N-terminal GST tag.
Catalog No. E27-11G
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| E27-11G-05 | 5 ug | $226 | |
| E27-11G-10 | 10 ug | $325 | |
| E27-11G-BULK | BULK | Contact Us |
Overview:
HER2 gene encodes a cell-surface glycoprotein tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER2 is an oncogene and overexpression of unaltered HER2 coding sequences in NIH 3T3 cells results in cellular transformation and tumorigenesis (1). HER2 is amplified in about 30% of primary human breast malignancies and overexpression of HER2 is associated with the most aggressive tumors that show uncontrolled proliferation, resistance to apoptosis and increased motility (2).
Gene Aliases:
NEU; NGL; HER2; TKR1; ERBB2; c-erb B2; HER-2/neu
Genbank Number:
References:
1. Hudziak, R M. et al: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63.
2. Badache, A. et al: The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):13-25.
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
|
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
|
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
~116 kDa
J Novotny Chris et al., Overcoming resistance to HER2 inhibitors through state-specific kinase binding Nature Chemical Biology November 2016 10.1038/nchembio.2171
Imami Koshi et al., Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Molecular and Cellular Proteomics September 2012 10.1074/mcp.M112.019919
Y Dunkel et al., Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers FASEB Journal November 2016 10.1096/fj.201600500
L. Disis Mary et al., HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers Cancer Immunology, Immunotherapy February 2014 10.1007/s00262-013-1489-4
A Chamas et al., Purification and immunodetection of the complete recombinant HER-2[neu] receptor produced in yeast. Protein Expression and Purification January 2015 10.1016/j.pep.2014.10.004
et al., Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities Nature cell biology April 2020
et al., Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens Oncotarget February 2017
AKT/PKB Pathway, Cancer, ERK/MAPK Pathway, Receptor Tyrosine Kinases
STAY CONNECTED
Fax: 1-604-232-4601
Toll Free: 1-866-954-6273
info@signalchem.com